Cancer immunotherapy has become a significant therapeutic strategy in oncology, particularly with respect to CTLA-4 and the interaction between programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) [1–7], which has been approved for the treatment of several human cancers [5, 6, 8–10]. The gene discussed is CD274; the disease is cancer.